⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivopril SCHEMBL120071 | 1.00 | — | — | |
| Pivopril SCHEMBL120072 | 1.00 | — | — | |
| SCHEMBL682441 | 0.99 | — | — | |
| SCHEMBL683304 | 0.99 | — | — | |
| SCHEMBL683661 | 0.99 | — | — | |
| SCHEMBL683238 | 0.95 | — | — | |
| SCHEMBL683559 | 0.86 | — | — | |
| SCHEMBL683645 | 0.86 | — | — | |
| SCHEMBL10739009 | 0.85 | — | — | |
| SCHEMBL683648 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662987-B2 | Oxidation of 1-acyl alkyl compound under anhydrous condition | XENOPORT, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20080255073-A1 | COMPOUNDS FOR SUSTAINED RELEASE OF ORALLY DELIVERED DRUGS | XONOPORT, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-4549992-A | Antihypertensive amides | USV PHARMACEUTICAL CORP. (US) | 1985-10-29 | — | — | US | claimed |
| US-8642644-B2 | Ophthamological drugs | DUKE UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130017248-A1 | Cationic Liposomes And Method of Use | Life Technologies Corporation (US) | 2013-01-17 | — | — | US | disclosed |
| US-8143437-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-8017776-B2 | Methods for synthesis of acyloxyalkyl compounds | XENOPORT, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| US-5498729-A | MIXED ANHYDRIDES | DOMB ABRAHAM J (IL) | 1996-03-12 | — | — | US | disclosed |
| US-5225401-A | Endopeptidase inhibitors for congestive heart failure | E. R. SQUIBB & SONS, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0527624-A2 | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure | E.R. Squibb & Sons, Inc. (US) | 1993-02-17 | — | — | EP | disclosed |
| US-5073641-A | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1991-12-17 | — | — | US | disclosed |
| EP-0278977-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. | BUNDGAARD HANS (DK) | 1988-08-24 | — | — | EP | disclosed |
| WO-1988001615-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1988-03-10 | — | — | WO | disclosed |
| US-4549992-A | Antihypertensive amides | USV PHARMACEUTICAL CORP. (US) | 1985-10-29 | — | — | US | disclosed |